• "Covid-19 patients who are not hospitalised: anticoagulation is rarely justified" (24 September 2020) > HERE
   
  
• "Proton pump inhibitors: increased risk of severe covid-19" (15 September 2020) > HERE
   
• "Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease" (24 July 2020) > HERE
   
• "Covid-19: remdesivir (Veklury°) authorised in the European Union, yet much remains unknown or uncertain" (13 July 2020) > HERE
   
• "Covid-19 and severe breathing problems: dexamethasone reduced mortality in one trial" (24 June 2020) > HERE
   
• "Lack of access to drug evaluation data: a recurrent problem, not confined to covid-19" (8 June 2020) > HERE
   
• "Covid-19 and  hydroxychloroquine  (Plaquenil°): new data  show no evidence of efficacy"  (16 April 2020) > HERE
   
• "New data on the  cardiac adverse effects  of the combination of  hydroxychloroquine  (Plaquenil°) with azithromycin (Zithromax° or other brands)" (16 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine (Plaquenil°): still no conclusive results" (15 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine: uncertainties and unanswered questions" (2 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine: caution" (30 March 2020) > HERE
   
• "Covid-19 and drug trials: what to make of the initial results?" (23 March 2020) > HERE
  
  
• For more information in French, see www.prescrire.org > Dans l'actualité
  

©Prescrire October 2020

For more updates, follow us on Facebook and Twitter

Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. > Follow us on Facebook or > Follow us on Twitter